QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:TTOO

T2 Biosystems (TTOO) Stock Forecast, Price & News

$0.18
-0.02 (-9.96%)
(As of 09/27/2023 ET)
Compare
Today's Range
$0.17
$0.22
50-Day Range
$0.09
$0.59
52-Week Range
$0.05
$5.72
Volume
71.03 million shs
Average Volume
48.94 million shs
Market Capitalization
$60.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

T2 Biosystems MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,282.0% Upside
$2.50 Price Target
Short Interest
Healthy
7.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.05mentions of T2 Biosystems in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$5.75 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

648th out of 976 stocks

Surgical & Medical Instruments Industry

68th out of 100 stocks


TTOO stock logo

About T2 Biosystems (NASDAQ:TTOO) Stock

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

TTOO Price History

TTOO Stock News Headlines

A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
What's Going On With T2 Biosystems Stock Today?
10% Owner of T2 Biosystems Makes $3.81M Sale
A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com
Why T2 Biosystems Stock Fell Today
T2 Biosystems Target of Unusually Large Options Trading (NASDAQ:TTOO)
Why T2 Biosystems Stock Is Cleared For Take Off
T2 Biosystems shares slide after snapping winning streak
T2 Biosystems shares fly, again, as memestock buzz keeps going
What's Going On With T2 Biosystems (TTOO) Stock?
See More Headlines
Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

TTOO Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTOO
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$2.50
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+1,232.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-62,000,000.00
Net Margins
-392.26%
Pretax Margin
-392.29%

Debt

Sales & Book Value

Annual Sales
$22.31 million
Book Value
($5.14) per share

Miscellaneous

Free Float
333,246,000
Market Cap
$62.58 million
Optionable
Optionable
Beta
0.27
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. John J. Sperzel III (Age 60)
    B.Sc., Pres, CEO & Chairman
    Comp: $865.5k
  • Mr. John M. Sprague CPA (Age 65)
    Chief Financial Officer
    Comp: $482.33k
  • Mr. Michael Terrence Gibbs Esq.Mr. Michael Terrence Gibbs Esq. (Age 52)
    Sr. VP, Gen. Counsel & Company Sec.
    Comp: $487.33k
  • Ms. Kelley J. Morgan (Age 47)
    Chief People Officer
  • Dr. Aparna Jha Ahuja M.D. (Age 56)
    Chief Medical Officer & Chairman of Scientific Advisory Board
  • Mr. Brett A. Giffin (Age 64)
    Chief Commercial Officer
  • Dr. Roger Smith Ph.D. (Age 58)
    Sr. VP of Science R&D













TTOO Stock - Frequently Asked Questions

Should I buy or sell T2 Biosystems stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares.
View TTOO analyst ratings
or view top-rated stocks.

What is T2 Biosystems' stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $2.50. On average, they predict the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 1,232.6% from the stock's current price.
View analysts price targets for TTOO
or view top-rated stocks among Wall Street analysts.

How have TTOO shares performed in 2023?

T2 Biosystems' stock was trading at $1.42 at the start of the year. Since then, TTOO stock has decreased by 86.8% and is now trading at $0.1876.
View the best growth stocks for 2023 here
.

When is T2 Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TTOO earnings forecast
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) posted its quarterly earnings data on Monday, August, 7th. The medical equipment provider reported ($0.08) EPS for the quarter. The medical equipment provider had revenue of $1.96 million for the quarter.

When did T2 Biosystems' stock split?

Shares of T2 Biosystems reverse split on Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its second quarter 2023 earnings guidance on Thursday, July, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.00 million-$2.00 million, compared to the consensus revenue estimate of $2.70 million.

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.33%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, Brett A Giffin, Goldman Sachs & Co Llc, Group LP Cr, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs.
View institutional ownership trends
.

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.19.

How much money does T2 Biosystems make?

T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $62.58 million and generates $22.31 million in revenue each year.

How many employees does T2 Biosystems have?

The company employs 158 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080.

This page (NASDAQ:TTOO) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -